Table of Contents
Chapter 1 Pharmacovigilance Market: Research Methodology & Scope
1.1 Market Segmentation & Scope
1.1.1 Product Life Cycle
1.1.2 Service Provider
1.1.3 Type
1.1.4 Process Flow
1.1.5 Therapeutic Area
1.1.6 End-Use
1.1.7 Regional Scope
1.1.8 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research:
1.3.5 Details Of Primary Research
1.3.5.1 Data For Primary Interviews In North America
1.3.5.2 Data For Primary Interviews In Europe
1.3.5.3 Data For Primary Interviews In Apac
1.3.5.4 Data For Primary Interviews In Latin America
1.3.5.5 Data For Primary Interviews In Mea
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Top Down Market Estimation
1.6.1.2 Cagr Calculation
1.6.1.3 Key Report Updates
1.7 List Of Secondary Sources
1.8 List Of Abbreviations
1.9 Market Definitions
1.10 Report Objectives
1.10.1 Objective 1:
1.10.2 Objective 2:
Chapter 2 Pharmacovigilance Market: Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot (Product Life Cycle & Service Provider)
2.3 Segment Snapshot (Type & Therapeutic Area)
2.4 Segment Snapshot (Process Flow & End Use)
2.5 Competitive Landscape Snapshot
Chapter 3 Pharmacovigilance Market: Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Analysis
3.1.2 Ancillary Market Analysis
3.2 Penetration & Growth Prospect Mapping
3.3 Pharmacovigilance Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Growing Drug Consumption And Drug Development Rates
3.3.1.2 Increasing Incidence Of Adr And Drug Toxicity
3.3.1.3 Increasing Trend Of Outsourcing Pharmacovigilance Services
3.3.1.4 Increasing Externalization Of Clinical Trial Studies By Large Pharmaceutical And Biopharmaceutical Companies
3.3.1.5 Increasing Regulatory Burden On Manufacturers
3.3.1.6 Introduction Of Technologically Advanced Software Services
3.3.1.7 Constantly Rising Investment On R&D By Healthcare Companies
3.3.1.8 Partnerships And Collaborations Between Market Players
3.3.2 Market Restraint Analysis
3.3.2.1 Shortage Of Skilled Labor
3.3.2.2 Expensive Technology For Small And Mid-Sized Player
3.3.2.3 Lack Of Recognition
3.3.2.4 Scarcity Of Integration Standards
3.3.3 Industry Challenges
3.4 Pharmacovigilance Market Analysis Tools: Porters
3.5 SWOT Analysis, By Factor (Political & Legal, Economic, And Technological)
3.6 Value Chain Analysis
3.6.1 Preclinical
3.6.2 Clinical
3.6.3 PMA
3.7 Mapping of Life Cycle against Service Offering and Their Demand
3.8 Regulatory Framework
3.8.1 List Of Regulatory Bodies By Country
3.9 Organization Structure Introduction
3.10 Pricing Models
3.10.1 Drug Safety Budget Allocation By Activities
3.10.2 By Development Phase
3.10.3 By Therapeutic Area
3.10.4 Pricing Level
3.10.4.1 Project Management
3.10.4.2 Case Processing
3.10.4.3 Adr Reporting
3.10.4.4 Medical Writing
3.10.4.5 Drug Safety Management
3.11 Technology Timeline Overview
3.11.1 Changing Technology & Adoption
3.11.1.1 Social Media
3.11.1.2 Literature Screening
3.11.1.3 Automation And Ai
3.11.1.4 Big Data Analytics In Pv
3.12 Impact Of Covid-19
3.12.1 Recent Developments & Strategic Outcomes
3.12.1.1 Regulatory Requirements/Changes Due To Covid-19
3.12.2 Strategies Implemented By Companies
3.12.2.1 Iqvia
3.12.2.2 Paraxel International Corporation
3.12.2.3 Bioclinica
3.12.2.4 Pharmaceutical Product Development (Ppd)
3.12.2.5 Ibm Corporation
3.12.2.6 Icon, Plc
3.12.2.7 Pra Health Sciences
3.12.2.8 Covance Inc
3.12.2.9 Arisglobal
3.12.2.10 Linical Accelovance
3.12.2.11 Laboratory Corporation Of America Holdings
3.13 Market Trends
3.13.1 Scaling Of Resources
3.13.2 Automation In Pharmacovigilance
3.14 Impact Of Inflation
3.15 Comparative Analysis Between Medical Writing Vs Medical Safety Review
3.15.1 Medical Writing Market Outlook, 2022
3.15.1.1 Medical Writing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
3.15.2 Medical Safety Review Market Outlook, 2022
3.15.2.1 Medical Safety Review Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 4 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis
4.1 Product Life Cycle Market Share Analysis, 2022 & 2030
4.2 Product Life Cycle Dashboard
4.3 Market Definition And Scope
4.3.1 Preclinical
4.3.1.1 Preclinical Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3.2 Phase I
4.3.2.1 Phase I Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3.3 Phase Ii
4.3.3.1 Phase Ii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3.4 Phase Iii
4.3.4.1 Phase Iii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3.5 Phase Iv
4.3.5.1 Phase Iv Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 5 Pharmacovigilance Market: Service Provider Estimates & Trend Analysis
5.1 Service Provider Market Share Analysis, 2023 & 2030
5.2 Service Provider Dashboard
5.3 Market Definition And Scope
5.3.1 In House
5.3.1.1 In House Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.2 Contract Outsourcing
5.3.2.1 Contract Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis
6.1 Type Market Share Analysis, 2023 & 2030
6.2 Type Dashboard
6.3 Market Definition And Scope
6.3.1 Spontaneous Reporting
6.3.1.1 Spontaneous Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.2 Intensified Adr Reporting
6.3.2.1 Intensified Adr Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.3 Targeted Spontaneous Reporting
6.3.3.1 Targeted Spontaneous Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.4 Cohort Event Monitoring (Cem)
6.3.4.1 Cem Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.5 Ehr Mining
6.3.5.1 Ehr Mining Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis
7.1 Process Flow Market Share Analysis, 2023 & 2030
7.2 Process Flow Dashboard
7.3 Market Definition And Scope
7.3.1 Case Data Management
7.3.1.1 Case Data Management Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.1.1.1 Case Logging
7.3.1.1.1.1 Case Logging Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.1.1.2 Case Data Analysis
7.3.1.1.2.1 Case Data Analysis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.1.1.3 Medical Reviewing And Reporting
7.3.1.1.3.1 Medical Reviewing And Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.2 Signal Detection
7.3.2.1 Signal Detection Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.2.1.1 Adverse Event Logging
7.3.2.1.1.1 Adverse Event Logging Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.2.1.2 Adverse Event Analysis
7.3.2.1.2.1 Adverse Event Analysis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.2.1.3 Adverse Event Review & Reporting
7.3.2.1.3.1 Adverse Event Review & Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.3 Risk Mamangement System
7.3.3.1 Risk Management System Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.3.1.1 Risk Evaluation System
7.3.3.1.1.1 Risk Evaluation System Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.3.1.2 Risk Mitigation System
7.3.2.1.2.1 Risk Mitigation System Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis
8.1 Therapeutic Area Market Share Analysis, 2023 & 2030
8.2 Therapeutic Area Dashboard
8.3 Market Definition And Scope
8.3.1 Oncology
8.3.1.1 Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.2 Neurology
8.3.2.1 Neurology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.3 Cardiology
8.3.3.1 Cardiology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.4 Respiratory Systems
8.3.4.1 Respiratory Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.5 Others
8.3.5.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 9 Pharmacovigilance Market: End-Use Estimates & Trend Analysis
9.1 End-Use Market Share Analysis, 2023 & 2030
9.2 End-Use Dashboard
9.3 Market Definition And Scope
9.3.1 Pharmacuticals
9.3.1.1 Pharmaceuticals Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.2 Biotechnology Companies
9.3.2.1 Biotechnology Companies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.3 Medical Device Manufacturers
9.3.3.1 Medical Device Manufacturers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.4 Others
9.3.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 10 Pharmacovigilance Market: Regional Estimates & Trend Analysis, By, Product, Service Providers, Type, And End-Use
10.1 Regional Market Snapshot
10.2 North America
10.2.1 North America Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.2.2 U.S.
10.2.2.1 U.S. Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.2.2.2 Competitive Scenario
10.2.2.3 Regulatory Framework
10.2.3 Canada
10.2.3.1 Canada Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.2.3.2 Competitive Scenario
10.2.3.3 Regulatory Framework
10.3 Europe
10.3.1 Europe Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.3.2 Uk
10.3.2.1 Uk Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.3.2.2 Competitive Scenario
10.3.2.3 Regulatory Framework
10.3.3 Germany
10.3.3.1 Germany Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.3.3.2 Competitive Scenario
10.3.3.3 Regulatory Framework
10.3.4 France
10.3.4.1 France Pharmacovigilance Market Estimates And Forecasts, 2018– 2030 (Usd Million)
10.3.4.2 Competitive Scenario
10.3.4.3 Regulatory Framework
10.3.5 Italy
10.3.5.1 Italy Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.3.5.2 Competitive Scenario
10.3.5.3 Regulatory Framework
10.3.6 Spain
10.3.6.1 Spain Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.3.6.2 Competitive Scenario
10.3.6.3 Regulatory Framework
10.3.7 Russia
10.3.7.1 Russia Pharmacovigilance Market Estimates And Forecasts, 2018– 2030 (Usd Million)
10.3.7.2 Competitive Scenario
10.3.7.3 Regulatory Framework
10.3.8 Denmark
10.3.8.1 Denmark Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.3.8.2 Competitive Scenario
10.3.8.3 Regulatory Framework
10.3.9 Norway
10.3.9.1 Norway Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.3.9.2 Competitive Scenario
10.3.9.3 Regulatory Framework
10.3.10 Sweden
10.3.10.1 Sweden Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.3.10.2 Competitive Scenario
10.3.10.3 Regulatory Framework
10.4 Asia Pacific
10.4.1 Asia Pacific Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.2 Japan
10.4.2.1 Japan Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.2.2 Competitive Scenario
10.4.2.3 Regulatory Framework
10.4.3 China
10.4.3.1 China Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.3.2 Competitive Scenario
10.4.3.3 Regulatory Framework
10.4.4 India
10.4.4.1 India Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.4.2 Competitive Scenario
10.4.4.3 Regulatory Framework
10.4.5 Australia
10.4.5.1 Australia Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.5.2 Competitive Scenario
10.4.5.3 Regulatory Framework
10.4.6 Thailand
10.4.6.1 Thailand Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.6.2 Competitive Scenario
10.4.6.3 Regulatory Framework
10.4.7 South Korea
10.4.7.1 South Korea Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.7.2 Competitive Scenario
10.4.7.3 Regulatory Framework
10.5 Latin America
10.5.1 Latin America Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.2 Brazil
10.5.2.1 Brazil Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.2.2 Competitive Scenario
10.5.2.3 Regulatory Framework
10.5.3 Mexico
10.5.3.1 Mexico Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.3.2 Competitive Scenario
10.5.3.3 Regulatory Framework
10.5.4 Argentina
10.5.4.1 Argentina Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.4.2 Competitive Scenario
10.5.4.3 Regulatory Framework
10.6 MEA
10.6.1 MEA Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.6.2 South Africa
10.6.2.1 South Africa Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.6.2.2 Competitive Scenario
10.6.2.3 Regulatory Framework
10.6.3 Saudi Arabia
10.6.3.1 Saudi Arabia Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.6.3.2 Competitive Scenario
10.6.3.3 Regulatory Framework
10.6.4 UAE
10.6.4.1 UAE Arabia Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.6.4.2 Competitive Scenario
10.6.4.3 Regulatory Framework
10.6.5 Kuwait
10.6.5.1 Kuwait Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.6.5.2 Competitive Scenario
10.6.5.3 Regulatory Framework
Chapter 11 Pharmacovigilance Market: Competitive Analysis
11.1 Market Participation Categorization
11.2 Public Companies
11.2.1 Company Market Position Analysis
11.2.2 Company Market Share
11.3 Private Companies
11.3.1 List Of Key Emerging Companies
11.4 Increasing Strategic Collaborations And Product Launch
11.5 Strategic Government Initiatives Which Include Collaborations
11.6 Competitors Increased Pv Awareness Program
11.7 Competitors Increased Collaboration And Outsourcing Of Operations
11.8 Consolidation Trends
11.9 Potential Customers
Chapter 12 Competitive Landscape
12.1 Company Profiles
12.1.1 Accenture
12.1.1.1 Company Overview
12.1.1.2 Service Benchmarking
12.1.1.3 Financial Performance
12.1.1.4 Strategic Initiatives
12.1.1.5 Swot Analysis
12.1.2 Clinquest Group B.V. (Linical Americas)
12.1.2.1 Company Overview
12.1.2.2 Service Benchmarking
12.1.2.3 Financial Performance
12.1.2.4 Strategic Initiatives
12.1.2.5 Swot Analysis
12.1.3 Iqvia
12.1.3.1 Company Overview
12.1.3.2 Service Benchmarking
12.1.3.3 Financial Performance
12.1.3.4 Strategic Initiatives
12.1.3.5 Swot Analysis
12.1.4 Cognizant
12.1.4.1 Company Overview
12.1.4.2 Service Benchmarking
12.1.4.3 Financial Performance
12.1.4.4 Strategic Initiatives
12.1.4.5 Swot Analysis
12.1.5 Laboratory Corporation Of America Holdings
12.1.5.1 Company Overview
12.1.5.2 Service Benchmarking
12.1.5.3 Financial Performance
12.1.5.4 Strategic Initiatives
12.1.5.5 Swot Analysis
12.1.6 Ibm Corporation
12.1.6.1 Company Overview
12.1.6.2 Service Benchmarking
12.1.6.3 Financial Performance
12.1.6.4 Strategic Initiatives
12.1.6.5 Swot Analysis
12.1.7 Arisglobal
12.1.7.1 Company Overview
12.1.7.2 Service Benchmarking
12.1.7.3 Financial Performance
12.1.7.4 Strategic Initiatives
12.1.7.5 Swot Analysis
12.1.8 Icon Plc.
12.1.8.1 Company Overview
12.1.8.2 Service Benchmarking
12.1.8.3 Financial Performance
12.1.8.4 Strategic Initiatives
12.1.8.5 Swot Analysis
12.1.9 Capgemini
12.1.9.1 Company Overview
12.1.9.2 Service Benchmarking
12.1.9.3 Financial Performance
12.1.9.4 Strategic Initiatives
12.1.9.5 Swot Analysis
12.1.10 Itclinical
12.1.10.1 Company Overview
12.1.10.2 Service Benchmarking
12.1.10.3 Financial Performance
12.1.10.4 Strategic Initiatives
12.1.10.5 Swot Analysis
12.1.11 Take Solutions Limited
12.1.11.1 Company Overview
12.1.11.2 Service Benchmarking
12.1.11.3 Financial Performance
12.1.11.4 Strategic Initiatives
12.1.11.5 Swot Analysis
12.1.12 Parexel International Corporation.
12.1.12.1 Company Overview
12.1.12.2 Service Benchmarking
12.1.12.3 Financial Performance
12.1.12.4 Strategic Initiatives
12.1.12.5 Swot Analysis
12.1.13 Bioclinica, Inc.
12.1.13.1 Company Overview
12.1.13.2 Service Benchmarking
12.1.13.3 Financial Performance
12.1.13.4 Strategic Initiatives
12.1.13.5 Swot Analysis
12.1.14 Wipro
12.1.14.1 Company Overview
12.1.14.2 Service Benchmarking
12.1.14.3 Financial Performance
12.1.14.4 Strategic Initiatives
12.1.14.5 Swot Analysis
12.1.15 United Biosource Llc
12.1.15.1 Company Overview
12.1.15.2 Service Benchmarking
12.1.15.3 Financial Performance
12.1.15.4 Strategic Initiatives
12.1.15.5 Swot Analysis
12.1.16 Fmd K&L (Clinchoice)
12.1.16.1 Company Overview
12.1.16.2 Service Benchmarking
12.1.16.3 Financial Performance
12.1.16.4 Strategic Initiatives
12.1.16.5 Swot Analysis
Chapter 13 Winning Strategies
13.1 Key Winning/Scoring Criteria
13.1.1 By Categories
13.1.1.1 Pharmaceuticals
13.1.1.2 Biotech Companies
13.1.1.3 Medical Device Companies
13.2 Key Vendor Selection Factors
13.2.1 By Category
13.2.2 By Company Size
13.2.2.1 Key Takeaways
Chapter 14 Switching Cost Analysis
List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviation
Table 4 Types of ADRs
Table 5 Adverse Drug Events (ADEs) in hospitals
Table 6 Pharmacovigilance outsourcing services insights
Table 7 List of regulations, by country
Table 8 Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
Table 9 Case management costing by year
Table 10 Price by case processing volume
Table 11 Subscription services for medical manuscript writing
Table 12 Total literature searches (2013 - 2022)
Table 13 Instances of failed phase I clinical trials for COVID-19 vaccine
Table 14 Recruiting phase II clinical trials for oncology
Table 15 Outsourcing trend observed in pharmaceutical companies
Table 16 Recent Market Events
Table 17 List of Major Deals & Acquisitions
List of Figures
Fig. 1 Pharmacovigilance market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Primary interviews in North America
Fig. 6 Primary interviews in Europe
Fig. 7 Primary interviews in APAC
Fig. 8 Primary interviews in Latin America
Fig. 9 Primary interviews in MEA
Fig. 10 Market research approaches
Fig. 11 Value-chain-based sizing & forecasting
Fig. 12 QFD modeling for market share assessment
Fig. 13 Market formulation & validation
Fig. 14 Timeline of pharmacovigilance for a drug from development (premarket to post marketing)
Fig. 15 Market Snapshot
Fig. 16 Segment Snapshot (Product Life Cycle & Service Provider)
Fig. 17 Segment Snapshot ( Type & Therapeutic Area)
Fig. 18 Segment Snapshot (Process Flow & End Use))
Fig. 19 Competitive Landscape Snapshot
Fig. 20 Penetration & growth prospect mapping
Fig. 21 Pharmacovigilance market dynamics
Fig. 22 Porter’s five force model
Fig. 23 Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 24 Pharmacovigilance & Patient Safety Services - Product Life Cycle
Fig. 25 PV department
Fig. 26 PV organization structure
Fig. 27 Estimated budget allocation of drug safety activities at global and country-level
Fig. 28 Comparison between estimated global and country-level drug safety budget allocation
Fig. 29 Average % of drug safety budget contributed by function at a global level
Fig. 30 Pharmacovigilance system cost for small-sized firms and larger-sized firms
Fig. 31 Clinical trial cost by phase (%)
Fig. 32 Selected clinical trials costs based on technology
Fig. 33 Estimated cost of developing therapeutic medical device in the U.S.
Fig. 34 The average monthly cost of illness due to ADRs
Fig. 35 Medical Writers Employers by Industry
Fig. 36 Trending topics on social media (2017)
Fig. 37 ADR detection and from social media data
Fig. 38 Common literature automation tool flow
Fig. 39 Automation processes in PV
Fig. 40 Deterrents to Leveraging the Cloud (Oracle Survey)
Fig. 41 The three-step process to compute signal statistics from search log using big data
Fig. 42 Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
Fig. 43 Pharma & Biotech R&D expense growth, 2020 (%)
Fig. 44 Medical writing market outlook, 2022 (USD Million)
Fig. 45 Medical writing market, 2018 - 2030 (USD Million)
Fig. 46 Global medical safety review market, 2018 - 2030 (USD Million)
Fig. 47 Pharmacovigilance market: Product life cycle movement analysis
Fig. 48 Pharmacovigilance market product life cycle dashboard
Fig. 49 Global Preclinical market, 2018 - 2030 (USD Million)
Fig. 50 Global Phase I market, 2018 - 2030 (USD Million)
Fig. 51 Global Phase II market, 2018 - 2030 (USD Million)
Fig. 52 Global Phase III market, 2018 - 2030 (USD Million)
Fig. 53 Adverse events reported in FAERS system, 2019-2022
Fig. 54 Global Phase IV market, 2018 - 2030 (USD Million)
Fig. 55 Pharmacovigilance market: Service provider movement analysis
Fig. 56 Pharmacovigilance Service provider dashboard
Fig. 57 Global In-house market, 2018 - 2030 (USD Million)
Fig. 58 Global contract outsourcing market, 2018 - 2030 (USD Million)
Fig. 59 Pharmacovigilance market: Type movement analysis
Fig. 60 Pharmacovigilance type dashboard
Fig. 61 Global spontaneous reporting market, 2018 - 2030 (USD Million)
Fig. 62 Global intensified ADR reporting market, 2018 - 2030 (USD Million)
Fig. 63 Global targeted spontaneous reporting market, 2018 - 2030 (USD Million)
Fig. 64 Global CEM market, 2018 - 2030 (USD Million)
Fig. 65 Global EHR mining market, 2018 - 2030 (USD Million)
Fig. 66 Pharmacovigilance market: Process flow movement analysis
Fig. 67 Pharmacovigilance market process flow dashboard
Fig. 68 Global case data management market, 2018 - 2030 (USD Million)
Fig. 69 Global case logging market, 2018 - 2030 (USD Million)
Fig. 70 Global case data analysis market, 2018 - 2030 (USD Million)
Fig. 71 Global medical reviewing and reporting market, 2018 - 2030 (USD Million)
Fig. 72 Global signal detection market, 2018 - 2030(USD Million)
Fig. 73 Global adverse event logging market, 2018 - 2030 (USD Million)
Fig. 74 Global adverse event analysis market, 2018 - 2030 (USD Million)
Fig. 75 Global adverse event review & reporting market, 2018 - 2030 (USD Million)
Fig. 76 Global risk management system market, 2018 - 2030 (USD Million)
Fig. 77 Global Risk Evaluation System market, 2018 - 2030 (USD Million)
Fig. 78 Global risk mitigation system market, 2018 - 2030 (USD Million)
Fig. 79 Pharmacovigilance market: Therapeutic area movement analysis
Fig. 80 Pharmacovigilance market therapeutic area dashboard
Fig. 81 Global oncology market, 2018 - 2030 (USD Million)
Fig. 82 Global neurology market, 2018 - 2030 (USD Million)
Fig. 83 Global cardiology market, 2018 - 2030 (USD Million)
Fig. 84 Global respiratory systems market, 2018 - 2030 (USD Million)
Fig. 85 Global others market, 2018 - 2030 (USD Million)
Fig. 86 Pharmacovigilance market: End-use movement analysis
Fig. 87 Pharmacovigilance market end-use dashboard
Fig. 88 Global pharmaceuticals market, 2018 - 2030 (USD Million)
Fig. 89 Global biotechnology companies’ market, 2018 - 2030 (USD Million)
Fig. 90 Global medical device manufacturers market, 2018 - 2030 (USD Million)
Fig. 91 Global others market, 2018 - 2030 (USD Million)
Fig. 92 Regional market place: Key takeaways
Fig. 93 North America pharmacovigilance market, 2018- 2030 (USD Million)
Fig. 94 U.S. key country dynamics (Part 1)
Fig. 95 U.S. key country dynamics (Part 2)
Fig. 96 U.S. pharmacovigilance market, 2018 - 2030(USD Million)
Fig. 97 Canada key country dynamics (Part 1)
Fig. 98 Canada key country dynamics (Part 2)
Fig. 99 Canada pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 100 Europe pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 101 UK key country dynamics (Part 1)
Fig. 102 UK key country dynamics (Part 2)
Fig. 103 UK pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 104 Germany key country dynamics (Part 1)
Fig. 105 Germany key country dynamics (Part 2)
Fig. 106 Germany pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 107 France key country dynamics (Part 1)
Fig. 108 France key country dynamics (Part 2)
Fig. 109 France pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 110 Italy key country dynamics (Part 1)
Fig. 111 Italy key country dynamics (Part 2)
Fig. 112 Italy pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 113 Spain key country dynamics (Part 1)
Fig. 114 Spain key country dynamics (Part 2)
Fig. 115 Spain pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 116 Russia key country dynamics
Fig. 117 Russia pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 118 Denmark key country dynamics (Part 1)
Fig. 119 Denmark key country dynamics (Part 2)
Fig. 120 Denmark pharmacovigilance market estimates and forecasts, 2018 - 2030, (USD Million)
Fig. 121 Norway key country dynamics (Part 1)
Fig. 122 Norway key country dynamics (Part 2)
Fig. 123 Norway pharmacovigilance market estimates and forecasts, 2018 - 2030, (USD Million)
Fig. 124 Sweden key country dynamics (Part 1)
Fig. 125 Sweden key country dynamics (Part 2)
Fig. 126 Sweden pharmacovigilance market estimates and forecasts, 2018 - 2030, (USD Million)
Fig. 127 Asia Pacific Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 130 Japan pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 131 China key country dynamics (Part 1)
Fig. 132 China key country dynamics (Part 2)
Fig. 133 China pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 134 India key country dynamics (Part 1)
Fig. 135 India key country dynamics (Part 2)
Fig. 136 India pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 139 Australia pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 140 Thailand key country dynamics (Part 1)
Fig. 141 Thailand key country dynamics (Part 2)
Fig. 142 Thailand pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 145 South Korea pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 146 Latin America pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 149 Brazil pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 150 Mexico key country dynamics
Fig. 152 Mexico pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 155 Argentina pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 156 MEA pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 159 South Africa pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 162 Saudi Arabia pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 163 UAE key country dynamics (Part 1)
Fig. 164 UAE key country dynamics (Part 2)
Fig. 165 UAE pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 167 Kuwait pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 168 Market participant categorization
Fig. 169 Company market position analysis
Fig. 170 Estimated company market share analysis, 2022 (%)
Fig. 171 SWOT - Accenture
Fig. 172 SWOT - Linical Americas
Fig. 173 SWOT - IQVIA
Fig. 174 SWOT - Cognizant
Fig. 175 SWOT - Laboratory Corporation of America Holdings
Fig. 176 SWOT - IBM Corporation
Fig. 177 SWOT - ArisGlobal
Fig. 178 SWOT - ICON plc
Fig. 179 SWOT - Capgemini
Fig. 180 SWOT - ITClinical
Fig. 181 SWOT - Take Solutions
Fig. 182 SWOT - Parexel International Corporation
Fig. 183 SWOT - Clario
Fig. 184 SWOT - Wipro
Fig. 185 SWOT - United BioSource LLC
Fig. 186 SWOT - FMD K&L
Fig. 187 Commonly outsourced PV activities
Fig. 188 Vendor selection criteria